Transcatheter Tricuspid Valve Replacement With Novel Self-Expanding Valve: Secure Fixation in Insecure Anatomy.

Autor:	Blusztein DI; Division of Cardiology, Columbia University Irving Medical Center, New York, New York, USA., Hahn RT; Division of Cardiology, Columbia University Irving Medical Center, New York, New York, USA., Godoy Rivas C; Division of Cardiology, Columbia University Irving Medical Center, New York, New York, USA., George I; Division of Cardiology, Columbia University Irving Medical Center, New York, New York, USA., Kodali SK; Division of Cardiology, Columbia University Irving Medical Center, New York, New York, USA.
Jazyk:	angličtina
Zdroj:	JACC. Case reports [JACC Case Rep] 2023 Apr 19; Vol. 12, pp. 101773. Date of Electronic Publication: 2023 Apr 19 (Print Publication: 2023).
DOI:	10.1016/j.jaccas.2023.101773
Abstrakt:	Current transcatheter tricuspid therapies vary by design with different mechanisms of fixation, anchoring, and therapy. This is the first published report of transfemoral tricuspid valve replacement with the Intrepid device, a valve designed to anchor from annular perimeter oversizing, to treat torrential tricuspid regurgitation from leaflet impingement secondary to a ventricular septal defect occluder. ( Level of Difficulty: Advanced. ). Competing Interests: Dr Hahn has received speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, Medtronic, and Novartis; and has equity with Navigate. Dr George has received consulting honoraria from Zimmer Biomet, AtriCure, NEOS surgery, and Neptune Medical; is an advisory board member for Edwards Surgical, Medtronic Surgical, Trisol Medical, AbbVie, Johnson & Johnson, and Foldax Medical; holds equity in Valcare Medical, DurVena, CardioMech, VDyne, Mitre Medical, and MITRx; and has received institutional funding to Columbia University from Edwards Lifesciences, Medtronic, Abbott Vascular, Boston Scientific, and JenaValve. Dr Kodali has received institutional research support (no direct financial compensation) from Edwards Lifesciences, Medtronic, Boston Scientific, JenaValve, Phillips, and Abbott; has received consulting honoraria from Admedus, TriCares, Phillips, TriFlo, and Shifamed; and holds equity options with Dura Biotech, Micro Interventional Devices, Thubrikar Aortic Valve, Supira Medical, Admedus, Adona Medical, Tioga, and X-Dot. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu